JP2019517586A - カッパオピオイド受容体アゴニストの持続放出組成物 - Google Patents

カッパオピオイド受容体アゴニストの持続放出組成物 Download PDF

Info

Publication number
JP2019517586A
JP2019517586A JP2019516085A JP2019516085A JP2019517586A JP 2019517586 A JP2019517586 A JP 2019517586A JP 2019516085 A JP2019516085 A JP 2019516085A JP 2019516085 A JP2019516085 A JP 2019516085A JP 2019517586 A JP2019517586 A JP 2019517586A
Authority
JP
Japan
Prior art keywords
sustained release
substituted
release composition
pain
kappa opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019516085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517586A5 (https=
Inventor
ガネカール、ゴータム
Original Assignee
ジェイティー ファーマスーティカルズ、インク．
ジェイティー ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェイティー ファーマスーティカルズ、インク．, ジェイティー ファーマスーティカルズ、インク． filed Critical ジェイティー ファーマスーティカルズ、インク．
Publication of JP2019517586A publication Critical patent/JP2019517586A/ja
Publication of JP2019517586A5 publication Critical patent/JP2019517586A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019516085A 2016-06-03 2017-06-05 カッパオピオイド受容体アゴニストの持続放出組成物 Pending JP2019517586A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345583P 2016-06-03 2016-06-03
US62/345,583 2016-06-03
PCT/US2017/035874 WO2017210668A1 (en) 2016-06-03 2017-06-05 Sustained release compositions of kappa-opioid receptor agonist

Publications (2)

Publication Number Publication Date
JP2019517586A true JP2019517586A (ja) 2019-06-24
JP2019517586A5 JP2019517586A5 (https=) 2020-07-27

Family

ID=60478002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516085A Pending JP2019517586A (ja) 2016-06-03 2017-06-05 カッパオピオイド受容体アゴニストの持続放出組成物

Country Status (5)

Country Link
US (1) US20200316159A1 (https=)
EP (1) EP3463306A4 (https=)
JP (1) JP2019517586A (https=)
CN (1) CN109789094A (https=)
WO (1) WO2017210668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
CA3171225A1 (en) * 2020-03-18 2021-09-23 Bryan R. Wilson Oligosaccharide formulations of kappa opioid receptor agonists
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
MX2023012087A (es) * 2021-04-14 2024-02-27 Titan Pharmaceuticals Inc Implantes de agonistas de los receptores kappa-opioides para tratamiento del prurito.
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN114873741B (zh) * 2022-05-31 2023-03-14 南京大学 一种脱氮缓释碳源材料及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528422A (ja) * 2002-05-31 2005-09-22 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
JP2009538310A (ja) * 2006-05-26 2009-11-05 カラ セラピューティクス インコーポレイテッド 哺乳動物におけるプロラクチンを上昇させる方法
JP2010509343A (ja) * 2006-11-10 2010-03-25 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
JP2010534192A (ja) * 2007-05-01 2010-11-04 フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー 鎮痛化合物
JP2013241447A (ja) * 2006-11-10 2013-12-05 Cara Therapeutics Inc 合成ペプチドアミドおよびその二量体
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501788B (zh) * 2010-09-02 2015-10-01 含陰離子聚合物之抗破碎劑型

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528422A (ja) * 2002-05-31 2005-09-22 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
JP2009538310A (ja) * 2006-05-26 2009-11-05 カラ セラピューティクス インコーポレイテッド 哺乳動物におけるプロラクチンを上昇させる方法
JP2010509343A (ja) * 2006-11-10 2010-03-25 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
JP2013241447A (ja) * 2006-11-10 2013-12-05 Cara Therapeutics Inc 合成ペプチドアミドおよびその二量体
JP2010534192A (ja) * 2007-05-01 2010-11-04 フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー 鎮痛化合物
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE OPEN MEDICINAL CHEMISTRY JOURNAL, 2013, VOL.7, PP.16-22, JPN6021020825, ISSN: 0004947325 *

Also Published As

Publication number Publication date
EP3463306A1 (en) 2019-04-10
WO2017210668A1 (en) 2017-12-07
US20200316159A1 (en) 2020-10-08
CN109789094A (zh) 2019-05-21
EP3463306A4 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
JP2019517586A (ja) カッパオピオイド受容体アゴニストの持続放出組成物
KR20210134313A (ko) 심리적, 인지적, 행동적 및/또는 기분 장애의 치료를 위한 5ht 수용체 아고니스트를 포함하는 조성물 및 방법
EP3668993A1 (en) Methods of treating liver diseases
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
EP4359076B1 (en) Phenyl pyrrole aminoguanidine salts and formulations
US20090143335A1 (en) Modified absorption formulation of gaboxadol
CN102065865B (zh) 多发性骨髓瘤治疗
EP2934540B1 (en) Methods for treating gi tract disorders
JP5757544B2 (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
EP2968475A2 (en) Acth for treatment of acute respiratory distress syndrome
EP2334299A1 (en) Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
WO2022192488A1 (en) Endoxifen for treatment of ovarian cancer
CN100493512C (zh) 一种含氢氯噻嗪和盐酸可乐定的缓释制剂及其制备方法
US20200188379A1 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
KR101438546B1 (ko) 프레가발린을 포함하는 서방성 제제
US6333345B1 (en) Methods of using and compositions comprising N-desmethylzolpidem
US20230129787A1 (en) Methods for treating ovarian cancer
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
CN100467064C (zh) 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
JP5440502B2 (ja) 過敏性腸症候群の治療方法
CN112469410A (zh) 药物化合物在治疗亨廷顿病中的用途
RU2772432C2 (ru) Способы лечения рака яичника
HK40110368B (en) Phenyl pyrrole aminoguanidine salts and formulations
CN120960204A (zh) 圣草酚及其衍生物的新用途
BR122025026872A2 (pt) Forma de dosagem sólida oral de liberação imediata e seu uso

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221220